A growing number of UK women are reporting a dramatic increase in breast size following COVID-19 vaccination, with some ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid ...

Collection and testing of raw milk cheese will be done by the FDA amid outbreaks of the illness in several states.

Credit: jayk7 via Getty Images. Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A.

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

On Thursday, federal health officials reported some unsettling results. Some of the genetic samples contained mutations that in theory might help the bird flu virus, H5N1, infect people more easily.

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

A total of 30 sample question papers for Class X and 20 for Class XII have been distributed to students, providing them with an invaluable resource during their winter break. This initiative aims to ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer holds exclusive rights to BRAFTOVI in the Middle East, Canada, Latin America, Africa, and the US. Credit: ShU studio/Shutterstock. Pfizer has gained accelerated approval from the US Food and ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...